在NSCLC中用于突变选择性和可逆第四代EGFR-TKI临床开发的化学支架
Emiliano Laudadio1, Luca Mangano2, Cristina Minnelli3
1Department of Science and Engineering of Matter, Environment and Urban Planning, Marche Polytechnic University, 60131 Ancona, Italy.
ACS chemical biology
|March 29, 2024
概括
新的EGFRTKI正在开发中,以对抗非小细胞肺癌 (NSCLC) 的耐药性. 本综述涵盖了针对EGFR突变的下一代药物,如T790M和C797S.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 非小细胞肺癌 (NSCLC) 的向治疗主要使用氨酸激酶抑制剂 (TKI) 来对抗表皮生长因子受体 (EGFR) 突变.
- 癌细胞通过EGFR (EGFRM+) 的序列突变对现有的TKI产生抗性.
- 克服抵抗机制,包括T790M和C797S突变,对于有效的NSCLC治疗至关重要.
研究的目的:
- 审查开发新型,可逆,下一代EGFR技术知识的最新进展.
- 讨论在NSCLC中克服针对EGFR向治疗的获得性耐药性的策略.
- 为发现和开发针对突变EGFR的新抗癌药物提供指导方针.
主要方法:
- 关于癌症进展中的EGFR信号通路的当前文献综述.
- 对针对突变EGFR的已批准药物和候选药物的分析.
- 评估下一代EGFR技术技能的化学结构,结合方式,效力和选择性.
主要成果:
- 识别新兴的可逆下一代EGFR TKI,旨在克服T790M和C797S耐药性突变.
- 药物候选物的详细比较,基于它们对野生类型和突变EGFR的疗效.
- 关于EGFR信号传导在驱动癌症进展和治疗耐药性的作用的总结.
结论:
- 下一代EGFR TKIs在克服NSCLC中抵抗机制方面表现有前途.
- 了解药物向相互作用是开发更有效和选择性癌症疗法的关键.
- 这一审查为继续开发针对EGFR突变癌症的创新药物化学策略提供了理由.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.8K
15:05Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
8.6K
相关概念视频
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Enzyme-linked Receptors
78.3K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
78.3K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Receptor Tyrosine Kinases
12.8K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
12.8K
